27,651 Shares in Amgen, Inc. (AMGN) Acquired by Asset Advisors Investment Management LLC

Asset Advisors Investment Management LLC bought a new position in shares of Amgen, Inc. (NASDAQ:AMGN) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 27,651 shares of the medical research company’s stock, valued at approximately $5,732,000.

Other hedge funds also recently made changes to their positions in the company. LSV Asset Management raised its holdings in shares of Amgen by 3.2% in the second quarter. LSV Asset Management now owns 4,157,649 shares of the medical research company’s stock valued at $767,460,000 after purchasing an additional 128,865 shares during the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Amgen by 2.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 3,207,242 shares of the medical research company’s stock valued at $592,025,000 after purchasing an additional 72,205 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Amgen by 17.0% in the second quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock valued at $436,551,000 after purchasing an additional 343,690 shares during the last quarter. Bank of Montreal Can raised its holdings in shares of Amgen by 13.4% in the third quarter. Bank of Montreal Can now owns 2,328,857 shares of the medical research company’s stock valued at $482,749,000 after purchasing an additional 275,469 shares during the last quarter. Finally, Swiss National Bank raised its holdings in shares of Amgen by 3.2% in the second quarter. Swiss National Bank now owns 2,227,926 shares of the medical research company’s stock valued at $411,253,000 after purchasing an additional 69,500 shares during the last quarter. Hedge funds and other institutional investors own 82.37% of the company’s stock.

NASDAQ:AMGN opened at $189.08 on Wednesday. Amgen, Inc. has a 1-year low of $163.31 and a 1-year high of $210.19. The company has a debt-to-equity ratio of 2.03, a current ratio of 3.39 and a quick ratio of 3.12. The firm has a market capitalization of $120.38 billion, a P/E ratio of 15.03, a PEG ratio of 1.80 and a beta of 1.40.



Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.45 by $0.24. Amgen had a net margin of 10.19% and a return on equity of 43.18%. The business had revenue of $5.90 billion during the quarter, compared to analysts’ expectations of $5.78 billion. During the same period last year, the business earned $3.27 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Amgen, Inc. will post 14.02 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 7th. Investors of record on Friday, November 16th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Thursday, November 15th. This represents a $5.28 annualized dividend and a dividend yield of 2.79%. Amgen’s dividend payout ratio is presently 41.97%.

A number of analysts have recently issued reports on the stock. Oppenheimer reiterated a “buy” rating and issued a $224.00 price objective on shares of Amgen in a report on Tuesday, October 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a $220.00 price objective on shares of Amgen in a report on Friday, August 24th. Morgan Stanley lifted their price objective on shares of Amgen from $210.00 to $212.00 and gave the company an “overweight” rating in a report on Thursday, October 11th. Leerink Swann set a $209.00 price objective on shares of Amgen and gave the company a “hold” rating in a report on Monday, September 17th. Finally, Cantor Fitzgerald set a $223.00 price objective on shares of Amgen and gave the company a “neutral” rating in a report on Monday, October 8th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $205.16.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

See Also: Understanding each part of a balance sheet

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply